Cite
MLA Citation
Matteo Santoni et al.. “Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis.” Expert review of pharmacoeconomics & outcomes research, vol. 22, 2022, pp. 45–51. http://access.bl.uk/ark:/81055/vdc_100148639647.0x00002b